Monday, November 19, 2018 6:40:13 AM
Interesting to see Takeda pressing ahead with the expensive acquisition of Shire
https://www.fiercepharma.com/pharma/former-takeda-chairman-privately-opposes-shire-buyout-ft
but trying to sell off the Shire treatment for inflammatory bowel disease due to its previous acquisition:
https://pharmaphorum.com/news/takeda-proposes-selling-shires-ibd-treatment-after-merger/
The valuation of that sale could be a catalyst with respect to Etrasimod.
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM